Thrombocytopenia

A low platelet count often is present in a person with acute leukemia, either from bone marrow replacement or from the bone marrow suppressive effects of the leukemia itself; from platelet consumption as a sequela of the disease or infection; or from the myelosuppres-sive effects of antileukemic chemotherapy. The incidence of serious spontaneous hemorrhage increases when the platelet count falls below 10,000/mm3, and this should be the threshold for platelet transfusions in the absence of bleeding. Using a platelet count of 10,000/mm3, as opposed to a count of 20,000/mm3, results in a similar incidence of bleeding complications and a 21.5% reduction in platelet use.145

non-Hodgkin's lymphoma. Cancer 65(5):1072-1073, 1990.

13. Boccia RV, Longo DL, Lieber ML, Jaffe ES, Fisher RI: Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma. Cancer 56(9):2295-2297, 1985.

14. Vaisban E, Zaina A, Braester A, Manaster J, Horn Y: Acute tumor lysis syndrome induced by high-dose corticosteroids in a patient with chronic lymphatic leukemia. Ann Hematol 80(5):314-315, 2001.

15. Simmons ED, Somberg KA: Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 67(8):2062-2065, 1991.

16. Benekli M, Gullu IH, Savas MC, et al.: Acute tumor lysis syndrome following intrathecal methotrexate. Leuk Lymphoma 22(3-4):361-363, 1996.

17. Fleming DR, Doukas MA: Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma 8(4-5):315-318, 1992.

18. Fleming DR, Henslee-Downey PJ, Coffey CW: Radiation induced acute tumor lysis syndrome in the bone marrow transplant setting. Bone Marrow Transplant 8(3):235-236, 1991.

19. Dann EJ, Fineman R, Rowe JM: Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol 20(1): 354-355, 2002.

20. Jensen M, Winkler U, Manzke O, Diehl V, Engert A: Rapid tumor lysis in a patient with B-cell chronic lym-phocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, ritux-imab). Ann Hematol 77(1-2):89-91, 1998.

21. Bross PF, Beitz J, Chen G, et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490-1496, 2001.

22. Jones DP, Mahmoud H, Chesney RW: Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 9(2):206-212, 1995.

23. Zusman J, Brown DM, Nesbit ME: Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 289(25): 1335-1340, 1973.

24. Lawrence J: Critical care issues in the patient with hematologic malignancy. Semin Oncol Nurs 10(3): 198-207, 1994.

25. Wilson D, Stewart A, Szwed J, Einhorn LH: Cardiac arrest due to hyperkalemia following therapy for acute lymphoblastic leukemia. Cancer 39(5):2290-2293, 1977.

26. Arrambide K, Toto RD: Tumor lysis syndrome. Semin Nephrol 13(3):273-280, 1993.

27. Flombaum CD: Metabolic emergencies in the cancer patient. Semin Oncol 27(3):322-334, 2000.

28. Ezzone SA: Tumor lysis syndrome. Semin Oncol Nurs 15(3):202-208, 1999.

29. Pui CH, Relling MV, Lascombes F, et al.: Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11(11): 1813-1816, 1997.

30. Brogard JM, Coumaros D, Franckhauser J, Stahl A, Stahl J: Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 17(9):890-895, 1972.

31. Pui CH, Mahmoud HH, Wiley JM, et al.: Recombinant urate oxidase for the prophylaxis or treatment of hype-ruricemia in patients With leukemia or lymphoma.

32. Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G: Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 56(3):425-430, 1989.

33. Gouault Heilmann M, Chardon E, Sultan C, Josso F: The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 30(2):151-158, 1975.

34. Falanga A, Alessio MG, Donati MB, Barbui T: A new procoagulant in acute leukemia. Blood 71(4):870-875, 1988.

35. Falanga A, Consonni R, Marchetti M, et al.: Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. Leukemia 8(1):156-159, 1994.

36. De Stefano V, Teofili L, Sica S, et al.: Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promye-locytic leukemia. Blood 86(9):3535-3541, 1995.

37. Falanga A, Consonni R, Marchetti M, et al.: Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 92(1):143-151, 1998.

38. Francis RB, Jr., Seyfert U: Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations. J Lab Clin Med 110(5):541-547, 1987.

39. Bennett B, Booth NA, Croll A, Dawson AA: The bleeding disorder in acute promyelocytic leukaemia: fibri-nolysis due to u-PA rather than defibrination. Br J Haematol 71(4):511-517, 1989.

40. Schmidt W, Egbring R, Havemann K: Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. Thromb Res 6(4):315-329, 1975.

41. Sterrenberg L, Nieuwenhuizen W, Hermans J: Purification and partial characterization of a D-like fragment from human fibrinogen, produced by human leukocyte elastase. Biochim Biophys Acta 755(2): 300-306, 2002.

42. Kim J, Hajjar KA: Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 7:d341-348, 2002.

43. Barbui T, Falanga A: Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 27(6):593-604, 1996.

44. Goldberg MA, Ginsburg D, Mayer RJ, et al.: Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 69(1):187-191, 1987.

45. Kantarjian HM, Keating MJ, Walters RS, et al.: Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med 80(5):789-797, 1986.

46. Bassan R, Battista R, Viero P, et al.: Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia 9(2):238-243, 1995.

47. Tallman MS, Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79(3):543-553, 1992.

48. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F: Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 75(11):2112-2117, 1990.

49. Falanga A, Iacoviello L, Evangelista V, et al.: Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelo-cytic leukemia administered all-trans-retinoic acid. Blood 86(3):1072-1081, 1995.

50. Kooistra T, Opdenberg JP, Toet K, et al.: Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb Haemost 65(5):565-572, 1991.

51. Fenaux P, Chastang C, Chevret S, et al.: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94(4):1192-1200, 1999.

52. Hug V, Keating M, McCredie K, Hester J, Bodey GP, Freireich EJ: Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 52(5):773-779, 1983.

53. Dutcher JP, Schiffer CA, Wiernik PH: Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 5(9):1364-1372, 1987.

54. Lichtman MA, Heal J, Rowe JM: Hyperleukocytic leukaemia: rheological and clinical features and management. Baillieres Clin Haematol 1(3):725-746, 1987.

55. Slovak ML, Kopecky KJ, Wolman SR, et al.: Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612). Leuk Res 19(6):381-388, 1995.

56. Stucki A, Cordey A, Monai N, Schapira M, Spertini O: Activation of vascular endothelial cells by leukemic blast cells: a mechanism of leukostasis. Blood 86:435a, 1995.

57. Lester TJ, Johnson JW, Cuttner J: Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis. Am J Med 79(l):43-48, 1985.

58. Schwartz JH, Cannellos GP: Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. Blood 46(1):11-16, 1975

59. Grund FM, Armitage JO, Burns P: Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med 137(9):1246-1247, 1977.

60. Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ: Therapeutic leukapheresis in hyper-leucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 98(2):433-436, 1997.

61. Flasshove M, Schuette J, Sauerwein W, Hoeffken K, Seeber S: Pulmonary and cerebral irradiation for hyper-leukocytosis in acute myelomonocytic leukemia. Leukemia 8(10):1792, 1994.

62. Castaigne S, Chomienne C, Daniel MT, et al.: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76(9):1704-1709, 1990.

63. Huang ME, Ye YC, Chen SR, et al.: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72(2):567-572, 1988.

64. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117(4):292-296, 1992.

65. De Botton S, Dombret H, Sanz M, et al.: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 92(8):2712-2718, 1998.

66. Tallman MS, Andersen JW, Schiffer CA, et al.: Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95(1):90-95, 2000.

67. Avvisati G, Lo Coco F, Diverio D, et al.: AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 88(4):1390-1398, 1996.

68. Seale J, Delva L, Renesto P, et al.: All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. Leukemia 10(1):95-101, 1996.

69. Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T: All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol 93(2):360-366, 1996

70. Dubois C, Schlageter MH, de Gentile A, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, Degos L, et al.: Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelo-cytic leukemia. Leukemia 8(10):1750-1757, 1994.

71. Di Noto R, Schiavone EM, Ferrara F, Manzo C, Lo Pardo C, Del Vecchio L: All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukaemia blast cells. Br J Haematol 88(2): 247-255, 1994.

72. Wiley JS, Firkin FC: Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia 9(5):774-778, 1995.

73. Castaigne S, Lefebvre P, Chomienne C, Suc E, Rigal-Huguet F, Gardin C, Delmer A, Archimbaud E, Tilly H, Janvier M, et al.: Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood 82(12):3560-3563, 1993.

74. Chen GQ, Shen ZX, Wu F, et al.: Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 10(5):825-828, 1996.

75. Mower WJ, Hawkins JA, Nelson EW: Neutropenic enterocolitis in adults with acute leukemia. Arch Surg 121(5):571-574, 1986.

76. Steinberg D, Gold J, Brodin A: Necrotizing enterocolitis in leukemia. Arch Intern Med 131(4):538-544, 1973.

77. Avigan D, Richardson P, Elias A, et al.: Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer 83(3):409-414, 1998.

78. Gorschluter M, Glasmacher A, Hahn C, et al.: Severe abdominal infections in neutropenic patients. Cancer Invest 19(7):669-677, 2001.

79. Dietrich CF, Brunner V, Lembcke B: Intestinal ultrasound in rare small and large intestinal diseases.

Z Gastroenterol 36(11):955-970, 1998.

80. Buyukasik Y, Ozcebe OI, Haznedaroglu IC, et al.: Neutropenic enterocolitis in adult leukemias. Int J Hematol 66(1):47-55, 1997.

81. Till M, Lee N, Soper WD, Murphy RL: Typhlitis in patients with HIV-1 infection. Ann Intern Med 116 (12 Pt 1): 998-1000, 1992.

82. Ahsan N, Sun CC, Di John D: Acute ileotyphlitis as presenting manifestation of acute myelogenous leukemia. Am J Clin Pathol 89(3):407-409, 1988.

83. Kaste SC, Flynn PM, Furman WL: Acute lymphoblastic leukemia presenting with typhlitis. Med Pediatr Oncol 28(3):209-212, 1997.

84. Wade DS, Nava HR, Douglass HO Jr: Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 69(1):17-23, 1992.

85. Gootenberg JE, Abbondanzo SL: Rapid diagnosis of neutropenic enterocolitis (typhlitis) by ultrasonogra-phy. Am JPediatr Hematol Oncol 9(3):222-227, 1987.

86. Teefey SA, Montana MA, Goldfogel GA, Shuman WP: Sonographic diagnosis of neutropenic typhlitis. AJR Am J Roentgenol 149(4):731-733, 1987.

87. Adams GW, Rauch RF, Kelvin FM, Silverman PM, Korobkin M: CT detection of typhlitis. J Comput Assist Tomogr 9(2):363-365, 1985.

88. Shamberger RC, Weinstein HJ, Delorey MJ, Levey RH: The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 57(3):603-609, 1986.

89. Hanada T, Ono I, Hirano C, Kurosaki Y: Successful treatment of neutropenic enterocolitis with recombinant granulocyte colony stimulating factor in a child with acute lymphocytic leukaemia. Eur J Pediatr 149(11):811-812, 1990.

90. Wach M, Dmoszynska A, Wasik-Szczepanek E, Pozarowski A, Drop A, Szczepanek D: Neutropenic enterocolitis: a serious complication during the treatment of acute leukemias. Ann Hematol 83(8):522-526, 2004.

91. Timuragaoglu A, Duman A, Ongut G, Saka O, Karadogan I: The significance of autoantibodies in non-Hodgkin's lymphoma. Leuk Lymphoma 40(1-2):119-122, 2000.

92. Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 95(9):2786-2792, 2000.

93. Sallah S, Sigounas G, Vos P, Wan JY, Nguyen NP: Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance. Ann Oncol 11(12):1571-1577, 2000.

94. Xiros N, Binder T, Anger B, Bohlke J, Heimpel H: Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin's disease. Eur J Haematol 40(5):437-441, 1988.

95. Gesierich W, Munker R, Geiersberger U, Pohlmann H, Brack N, Hartenstein R: Spontaneous bleeding in a patient with malignant lymphoma: a case of acquired hemophilia. Onkologie 23(6):584-588, 2000.

96. Tiplady CW, Hamilton PJ, Galloway MJ: Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine. Clin Lab Haematol 22(3):163-165, 2000.

97. Hunault-Berger M, Rachieru P, Ternisien C, et al.: Acquired von Willebrand disease and lymphoprolifera-tive syndromes. Presse Med 30(5):209-212, 2001.

98. Rao KP, Kizer J, Jones TJ, Anunciado A, Pepkowitz SH, Lazarchick J: Acquired von Willebrand's syndrome associated with an extranodal pulmonary lymphoma. Arch Pathol Lab Med 112(1):47-50, 1988.

99. Malik U, Dutcher JP, Oleksowicz L: Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma: a case report and review of the literature. Cancer 82(9):1764-1768, 1998.

100. Genvresse I, Buttgereit F, Spath-Schwalbe E, Ziemer S, Eucker J, Possinger K: Arterial thrombosis associated with anticardiolipin and anti-beta2-glycoprotein-I antibodies in patients with non-Hodgkin's lymphoma: a report of two cases. Eur J Haematol 65(5):344-347, 2000.

101. Di Biagio E, Sanchez-Borges M, Desenne JJ, Suarez-Chacon R, Somoza R, Acquatella G: Eosinophilia in Hodgkin's disease: a role for interleukin 5. Int Arch Allergy Immunol 110(3):244-251, 1996.

102. Gallamini A, Carbone A, Lista P, et al.: Intestinal T-cell lymphoma with massive tissue and blood eosinophilia mediated by IL-5. Leuk Lymphoma 17(1-2):155-161, 1995.

103. Kojima H, Takei N, Mukai Y, et al.: Hemophagocytic syndrome as the primary clinical symptom of Hodgkin's disease. Ann Hematol 82(1):53-56, 2003.

104. Gordon BG, Kiwanuka J, Kadushin J: Autoimmune neutropenia and Hodgkin's disease: successful treatment with intravenous gammaglobulin. Am JPediatr Hematol Oncol 13(2):164-167, 1991.

105. Reid TJ, IIIrd, Mullaney M, Burrell LM, Redmond J, IIIrd, Mangan KF: Pure red cell aplasia after chemotherapy for Hodgkin's lymphoma: in vitro evidence for

T cell mediated suppression of erythropoiesis and response to sequential cyclosporin and erythropoietin. Am J Hematol 46(1):48-53, 1994.

106. Lugassy G: Non-Hodgkin's lymphoma presenting with amegakaryocytic thrombocytopenic purpura. Ann Hematol 73(1):41-42, 1996.

107. Da'as N, Polliack A, Cohen Y, et al.: Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol 67(3):158-164, 2001.

108. Ronco PM: Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 56(1):355-377, 1999.

109. Dabbs DJ, Striker LM, Mignon F, Striker G: Glomerular lesions in lymphomas and leukemias. Am J Med 80(1):63-70, 1986.

110. Rault R, Holley JL, Banner BF, el-Shahawy M: Glomerulonephritis and non-Hodgkin's lymphoma: a report of two cases and review of the literature. Am J Kidney Dis 20(1):84-89, 1992.

111. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H, 3rd, Mutasim D, Ariss-Abdo L, et al.: Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia.

N Engl J Med 323(25):1729-1735, 1990.

112. Schlesinger T, McCarron K, Camisa C, Anhalt G: Paraneoplastic pemphigus occurring in a patient with B-cell non-Hodgkin's lymphoma. Cutis 61(2):94-96, 1998.

113. Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, Anhalt GJ: The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 340(18):1406-1410, 1999.

114. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ: Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 66(2):142-144, 2001.

115. Gergely L, Varoczy L, Vadasz G, Remenyik E, Illes A: Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol 109(4):202-205, 2003.

116. Gille J, Spieth K, Kaufmann R: Sweet's syndrome as initial presentation of diffuse large B-cell lymphoma. J Am Acad Dermatol 46(2 Suppl Case Reports):S11-13, 2002.

117. Suvajdzic N, Dimcic Z, Cvijetic O, Colovic M: Sweet's syndrome associated with Hodgkin's disease. Haematologia (Budap) 29(2):157-158, 1998.

118. Chan LS, Hanson CA, Cooper KD: Concurrent eosinophilic fasciitis and cutaneous T-cell lymphoma. Eosinophilic fasciitis as a paraneoplastic syndrome of T-cell malignant neoplasms? Arch Dermatol 127(6): 862-865, 1991.

119. Vassallo C, Ciocca O, Arcaini L, et al.: Eosinophilic fol-liculitis occurring in a patient affected by Hodgkin lymphoma. Int J Dermatol 41(5):298-300, 2002.

120. Kim H, Kim MO, Ahn MJ, et al.: Eosinophilic fasciitis preceding relapse of peripheral T-cell lymphoma.

J Korean Med Sci 15(3):346-350, 2000.

121. Allen LE, Heaton ND, Hurst PA: Pyoderma gangreno-sum-an association with Hodgkin's disease. Clin Exp Dermatol 16(2):151, 1991.

122. Lucker GP, Steijlen PM: Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol 133(2):322-325, 1995.

123. Ono H, Yokozeki H, Katayama I, Nishioka K: Granuloma annulare in a patient with malignant lymphoma. Dermatology 195(1):46-47, 1997.

124. Arnold J, Berens N, Brocker EB, Goebeler M: Recurrent angio-oedema and solitary molluscum contagiosum as presenting signs of non-Hodgkin's B-cell lymphoma. Br J Dermatol 146(2):343-344, 2002.

125. Hammack J, Kotanides H, Rosenblum MK, Posner JB: Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 42(10):1938-1943, 1992.

126. Spyridonidis A, Fischer KG, Glocker FX, Fetscher S, Klisch J, Behringer D: Paraneoplastic cerebellar degeneration and nephrotic syndrome preceding Hodgkin's disease: case report and review of the literature. Eur J Haematol 68(5):318-321, 2002.

127. Graus F, Dalmau J, Valldeoriola F, et al.: Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. JNeuroimmunol 74(1-2):55-61, 1997.

128. Bernal F, Shams'ili S, Rojas I, et al.: Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 60(2):230-234, 2003.

129. Sillevis Smitt P, Kinoshita A, De Leeuw B, et al.: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342(1): 21-27, 2000.

130. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123 (Pt 7): 1481-1494, 2000.

131. Hughes RA, Britton T, Richards M: Effects of lymphoma on the peripheral nervous system. J R Soc Med 87(9): 526-530, 1994.

132. Vallat JM, De Mascarel HA, Bordessoule D, et al.: Non-Hodgkin malignant lymphomas and peripheral neu-ropathies-13 cases. Brain 118 ( Pt 5):1233-1245, 1995.

133. Re D, Schwenk A, Hegener P, Bamborschke S, Diehl V, Tesch H.:Guillain-Barre syndrome in a patient with non-Hodgkin's lymphoma. Ann Oncol 11(2):217-220, 2000.

134. Gorson KC, Ropper AH, Weinberg DH, Weinstein R: Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 24(6): 778-786, 2001.

135. Edoute Y, Haim N, Rinkevich D, Brenner B, Reisner SA: Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients. Am J Med 102(3):252-258, 1997.

136. Muggia FM: Overview of cancer-related hypercalcemia: epidemiology and etiology. Semin Oncol 17(2 Suppl 5): 3-9, 1990.

137. Daroszewska A, Bucknall RC, Chu P, Fraser WD: Severe hypercalcaemia in B-cell lymphoma: combined effects of PTH-rP, IL-6 and TNF. Postgrad Med J 75(889): 672-674, 1999.

138. Seymour JF, Gagel RF: Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82(5):1383-1394, 1993.

139. Bain BJ, Catovsky D, Ewan PW: Acquired angioedema as the presenting feature of lymphoproliferative disorders of mature B-lymphocytes. Cancer 72(11): 3318-3322, 1993.

140. Geha RS, Quinti I, Austen KF, Cicardi M, Sheffer A, Rosen FS: Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med 312(9):534-540, 1985.

141. Yalcin S, Aybar B, Ertekin C, Guloglu R: Use of a modified occlusal bite guard to treat self-induced traumatic macroglossia (two case reports). Ulus Travma Derg 7(1): 70-73, 2001.

142. Watterson J, Priest JR: Jaundice as a paraneoplastic phenomenon in a T-cell lymphoma. Gastroenterology 97(5): 1319-1322, 1989.

143. Yusuf MA, Elias E, Hubscher SG: Jaundice caused by the vanishing bile duct syndrome in a child with Hodgkin lymphoma. JPediatr Hematol Oncol 22(2):154-157, 2000.

144. Rossini MS, Lorand-Metze I, Oliveira GB, Souza CA: Vanishing bile duct syndrome in Hodgkin's disease: case report. Sao Paulo Med J 118(5):154-157, 2000.

145. Rebulla P, Finazzi G, Marangoni F, et al.: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 337(26):1870-1875, 1997.

This page intentionally left blank

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment